Alkermes plc $ALKS Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 18.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 134,387 shares of the company’s stock after purchasing an additional 21,067 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.08% of Alkermes worth $4,032,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Armstrong Advisory Group Inc. purchased a new stake in Alkermes in the second quarter valued at approximately $29,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Alkermes during the 2nd quarter valued at $49,000. Osaic Holdings Inc. grew its stake in shares of Alkermes by 56.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after buying an additional 701 shares during the period. EMC Capital Management acquired a new stake in shares of Alkermes during the 2nd quarter worth $69,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Alkermes in the 2nd quarter worth $82,000. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ALKS shares. Deutsche Bank Aktiengesellschaft lowered their price target on Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Royal Bank Of Canada increased their target price on shares of Alkermes from $45.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Jefferies Financial Group set a $56.00 price target on shares of Alkermes and gave the company a “buy” rating in a report on Tuesday, October 28th. Wells Fargo & Company decreased their price objective on shares of Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and an average price target of $44.69.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $30.38, for a total value of $273,420.00. Following the completion of the transaction, the executive vice president directly owned 69,740 shares of the company’s stock, valued at $2,118,701.20. This represents a 11.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 34,748 shares of company stock valued at $1,048,830. Insiders own 4.40% of the company’s stock.

Alkermes Stock Up 0.2%

NASDAQ ALKS opened at $29.66 on Friday. Alkermes plc has a fifty-two week low of $25.17 and a fifty-two week high of $36.45. The business has a 50 day moving average price of $29.26 and a two-hundred day moving average price of $29.05. The stock has a market cap of $4.90 billion, a PE ratio of 14.68 and a beta of 0.48.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.08. The business had revenue of $394.19 million for the quarter, compared to analysts’ expectations of $355.23 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. Sell-side analysts anticipate that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.